vs
Side-by-side financial comparison of Bio-Techne (TECH) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $199.5M, roughly 1.5× VIRTUS INVESTMENT PARTNERS, INC.). Bio-Techne runs the higher net margin — 12.8% vs 3.6%, a 9.3% gap on every dollar of revenue. On growth, VIRTUS INVESTMENT PARTNERS, INC. posted the faster year-over-year revenue change (-4.1% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -5.7%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
TECH vs VRTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $199.5M |
| Net Profit | $38.0M | $7.1M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | 7.7% |
| Net Margin | 12.8% | 3.6% |
| Revenue YoY | -6.4% | -4.1% |
| Net Profit YoY | 68.3% | -78.1% |
| EPS (diluted) | $0.24 | $1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $199.5M | ||
| Q4 25 | $295.9M | $208.0M | ||
| Q3 25 | — | $216.4M | ||
| Q2 25 | $317.0M | $210.5M | ||
| Q1 25 | $316.2M | $217.9M | ||
| Q4 24 | $297.0M | $233.5M | ||
| Q3 24 | $289.5M | $227.0M | ||
| Q2 24 | $306.1M | $224.4M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | $38.0M | $33.9M | ||
| Q3 25 | — | $31.3M | ||
| Q2 25 | $-17.7M | $42.7M | ||
| Q1 25 | $22.6M | $28.1M | ||
| Q4 24 | $34.9M | $39.5M | ||
| Q3 24 | $33.6M | $49.1M | ||
| Q2 24 | $40.6M | $26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — |
| Q1 26 | — | 7.7% | ||
| Q4 25 | 18.4% | 19.1% | ||
| Q3 25 | — | 21.7% | ||
| Q2 25 | -7.5% | 21.5% | ||
| Q1 25 | 12.2% | 16.8% | ||
| Q4 24 | 16.0% | 21.7% | ||
| Q3 24 | 13.8% | 24.3% | ||
| Q2 24 | 15.0% | 19.7% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 12.8% | 16.3% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | -5.6% | 20.3% | ||
| Q1 25 | 7.1% | 12.9% | ||
| Q4 24 | 11.7% | 16.9% | ||
| Q3 24 | 11.6% | 21.6% | ||
| Q2 24 | 13.3% | 11.6% |
| Q1 26 | — | $1.05 | ||
| Q4 25 | $0.24 | $5.15 | ||
| Q3 25 | — | $4.65 | ||
| Q2 25 | $-0.11 | $6.12 | ||
| Q1 25 | $0.14 | $4.05 | ||
| Q4 24 | $0.22 | $4.65 | ||
| Q3 24 | $0.21 | $5.71 | ||
| Q2 24 | $0.26 | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $136.6M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $93.6B |
| Total Assets | $2.5B | — |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $136.6M | ||
| Q4 25 | $172.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $162.2M | — | ||
| Q1 25 | $140.7M | — | ||
| Q4 24 | $177.5M | — | ||
| Q3 24 | $187.5M | — | ||
| Q2 24 | $152.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | $390.0M | ||
| Q3 25 | — | $390.6M | ||
| Q2 25 | $346.0M | $231.3M | ||
| Q1 25 | $330.0M | $231.7M | ||
| Q4 24 | $300.0M | $232.1M | ||
| Q3 24 | $300.0M | $237.5M | ||
| Q2 24 | $319.0M | $247.6M |
| Q1 26 | — | $93.6B | ||
| Q4 25 | $2.0B | $934.0M | ||
| Q3 25 | — | $918.7M | ||
| Q2 25 | $1.9B | $896.4M | ||
| Q1 25 | $2.0B | $893.7M | ||
| Q4 24 | $2.1B | $897.5M | ||
| Q3 24 | $2.1B | $889.0M | ||
| Q2 24 | $2.1B | $868.7M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $4.3B | ||
| Q3 25 | — | $3.9B | ||
| Q2 25 | $2.6B | $3.7B | ||
| Q1 25 | $2.6B | $3.7B | ||
| Q4 24 | $2.7B | $4.0B | ||
| Q3 24 | $2.7B | $3.6B | ||
| Q2 24 | $2.7B | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | 0.42× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | 0.18× | 0.26× | ||
| Q1 25 | 0.16× | 0.26× | ||
| Q4 24 | 0.14× | 0.26× | ||
| Q3 24 | 0.14× | 0.27× | ||
| Q2 24 | 0.15× | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
